+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevention of experimental coronavirus colds with intranasal alpha-2b interferon



Prevention of experimental coronavirus colds with intranasal alpha-2b interferon



Journal of Infectious Diseases 154(3): 443-447



Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41%) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score greater than 4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 041058889

Download citation: RISBibTeXText

PMID: 3016111


Related references

Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrobial Agents and ChemoTherapy 26(1): 31-34, 1984

Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. New England Journal of Medicine 314(2): 71-75, 1986

Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. Journal of Infectious Diseases 150(2): 174-180, 1984

Intranasal$Interferon- alpha_{2}$Treatment of Experimental Rhinoviral Colds. The Journal of Infectious Diseases 150(2): 174-180, 1984

Intranasal recombinant alpha 2b interferon treatment of naturally occurring common colds. Antimicrobial Agents & Chemotherapy 32(2): 224-230, 1988

Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. Clinical Infectious Diseases 33(11): 1865-1870, 2001

Tolerance and efficacy of recombinant intranasal interferon beta serine in preventing experimental and natural rhinovirus colds. Journal of Interferon Research 7(6): 691, 1987

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrobial Agents and ChemoTherapy 24(5): 713-715, 1983

Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet 2(8291): 186-188, 1982

Intranasal interferon alfa 2b treatment of natural rhinovirus colds. Clinical Research 35(3): 476A, 1987

Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. Journal of Infectious Diseases 148(3): 543-550, 1983

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrobial Agents and Chemotherapy 32(2): 224-230, 1988

Tolerance and efficacy of recombinant intranasal interferon beta serine in preventing rhinovirus colds. Clinical Research 35(3): 491A, 1987

Controlled trials of intranasal interferon alpha 2 in prevention of naturally acquired respiratory infections. Antiviral Researchc. Issue: 27, 1984

Changes in human nasal mucosa during experimental coronavirus common colds. Acta Oto-Laryngologica 107(3-4): 262-269, 1989